TICKERNERD
Menu
DRTSDRTSHealthcare · Biotechnology

DRTS Stock Forecast: Alpha Tau Medical Ltd. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$14
+3.62% on the day

The 5 Wall Street analysts covering Alpha Tau Medical Ltd. hold a median 12-month price target of $17 — +21.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.3B
Ticker Nerd rank
14/ 100
Median analyst target
$17
Analysts covering
5
Revenue$0.0
Operating income−$13.8M
Net income−$45.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.1%
1M
−5.0%
YTD
+183.4%
1Y
+262.5%
From 52W high
−9.5%
From 52W low
+304.3%
$3
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DRTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alpha Tau Medical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
14/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Size
41
Volatility
39
Revisions
29
Growth
27
Accruals
27
Issuance
25
Value
18
Quality
10

Momentum (95): The shares have been drifting up relative to others.

Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DRTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26DRTSHigh $30Median $17Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $8Median $17High $30

The green dot is the last close — the median target sits +21.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Oct 2026HC Wainwright & Co.ReiteratesBuy$16
3 Sept 2026BarclaysMaintainsOverweight$17 → $30
3 Sept 2026BarclaysMaintainsOverweight—
11 Aug 2026HC Wainwright & Co.MaintainsBuy$15 → $16
11 Aug 2026HC Wainwright & Co.MaintainsBuy—
22 July 2026HC Wainwright & Co.ReiteratesBuy—
22 July 2026HC Wainwright & Co.ReiteratesBuy$15
16 July 2026HC Wainwright & Co.ReiteratesBuy—
16 July 2026HC Wainwright & Co.ReiteratesBuy$15
4 June 2026BarclaysMaintainsOverweight—
4 June 2026HC Wainwright & Co.ReiteratesBuy—
2 June 2026HC Wainwright & Co.ReiteratesBuy—
28 May 2026BarclaysInitiatesOverweight—
20 May 2026HC Wainwright & Co.ReiteratesBuy—
19 May 2026Piper SandlerMaintainsNeutral—
12 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Ladenburg ThalmannMaintainsBuy—
11 Mar 2026CitigroupMaintainsBuy—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
4 Mar 2026Piper SandlerDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DRTS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DRTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Alpha Tau Medical Ltd. returned +262.5% against +14.8% for the S&P 500, dividends included.

DRTS vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26DRTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DRTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
4
Fundamentals

Alpha Tau Medical Ltd. (DRTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−26.5×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
29.4×

Cheaper than 3% of US stocks

EV / EBITDA
−24.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−141.7%

Higher than 10% of US stocks

Return on assets
−25.7%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alpha Tau Medical Ltd. (DRTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alpha Tau Medical Ltd. has a market value of $1.3B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$92.6M.

  • Shares outstanding: 90.2M.

  • Trailing P/E: −26.5×; forward P/E: −26.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alpha Tau Medical Ltd. employs 121 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

DRTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DRTSAlpha Tau Medical Ltd.$1.3B14
OMEROmeros Corp.$1.3B92
NKTRNektar Therapeutics$1.3B46
LBRXLB Pharmaceuticals, Inc.$1.3B16
INBXInhibrx Biosciences, Inc.$1.3B26
RAPPRapport Therapeutics, Inc.$1.2B71
GHRSGH Research Plc$1.4B53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alpha Tau Medical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DRTS news & analysis

Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange

GlobeNewsWire · 29 Oct 2026positive

Alpha Tau Medical announced its ordinary shares will join the Tel Aviv Stock Exchange’s TA-90 and TA-125 indices, effective Nov. 5, 2026. The company said funds tracking these benchmarks are expected to add its shares to their holdings.

Why it matters — DRTS watchers may note the index inclusion and the expected resulting holdings by funds that track the TASE benchmarks.

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

GlobeNewsWire · 22 Oct 2026positive

Alpha Tau Medical signed an MOU with Samsung Medical Center in Seoul to explore a potential clinical trial of Alpha DaRT for pancreatic cancer patients in South Korea. The company described this as Alpha DaRT’s first potential trial in the country.

Why it matters — The MOU marks a possible clinical-trial opportunity at a leading Korean oncology center, though a trial has not yet been confirmed.

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

GlobeNewsWire · 19 Oct 2026positive

The FDA approved an IDE supplement expanding Alpha Tau’s U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma from 10 to 20 patients, with additional endpoints and an interim analysis. The trial’s principal investigator authored an abstract accepted for presentation at the SNO 2026 Annual Meeting, its first appearance at a scientific meeting.

Why it matters — The expanded trial and planned scientific-meeting presentation provide DRTS watchers with updates on the clinical program for Alpha DaRT in recurrent glioblastoma.

Alpha Tau to Participate in October Investor Conferences

GlobeNewsWire · 5 Oct 2026neutral

Alpha Tau Medical announced that company management will participate in investor conferences in October 2026. The announcement was made on October 5, 2026, from Jerusalem.

Why it matters — DRTS watchers may learn more about the company's progress and outlook through management's presentations at these upcoming investor conferences.

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

Seeking Alpha · 4 Sept 2026positive

Alpha Tau is approaching a potential year-end inflection point, with glioblastoma (GBM) data expected before year-end and pancreatic data shortly after. Two of the first three GBM patients reportedly achieved a complete response, an outcome described as essentially unheard of in GBM.

Why it matters — A DRTS watcher would care because upcoming GBM and pancreatic data represent potential milestone catalysts for the company, with early GBM responses suggesting a possible breakthrough.

FAQ

Frequently asked questions about DRTS stock

What is the DRTS stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Alpha Tau Medical Ltd. have a median 12-month price target of $17, with estimates ranging from $8 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRTS stock a buy right now?

Of the 5 analysts covering Alpha Tau Medical Ltd., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alpha Tau Medical Ltd. 14 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRTS?

As at 4 Nov 2026, Alpha Tau Medical Ltd. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will DRTS stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +21.2% from the last close, and Ticker Nerd's factor model ranks Alpha Tau Medical Ltd. 14 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRTS stock forecast for 2030?

No analyst covering Alpha Tau Medical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $30 over the next 12 months.

How has DRTS stock performed over the past year?

Alpha Tau Medical Ltd. returned +262.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alpha Tau Medical Ltd. do?

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing Alpha DaRT, a targeted alpha-radiation platform designed for the treatment of solid tumors.

What is the latest news on DRTS?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange". Alpha Tau Medical announced its ordinary shares will join the Tel Aviv Stock Exchange’s TA-90 and TA-125 indices, effective Nov. 5, 2026. The company said funds tracking these benchmarks are expected to add its shares to their holdings.

Company

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing Alpha DaRT, a targeted alpha-radiation platform designed for the treatment of solid tumors. The company’s core work centers on research, clinical development, and commercialization of localized cancer therapies that deliver alpha particles directly inside tumor tissue while limiting exposure to surrounding healthy tissue. Alpha Tau Medical Ltd. is active in a range of oncology indications, including skin, oral, pancreatic, prostate, lung, liver, breast, and brain cancers, reflecting the broad potential use of its technology across difficult-to-treat solid tumors. Headquartered in Jerusalem, Israel, the company operates as a medical technology business serving the oncology sector and is centered on advancing precision radiation approaches for cancer care.

CEO Mr. Uzi Sofer · 121 employees · Israel · https://www.alphatau.com